In vivo dual-targeted chemotherapy of drug resistant cancer by rationally designed nanocarrier.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26491996.
- Also identified by DOI 10.1016/j.biomaterials.2015.09.030.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Multidrug resistance is one of major obstacles to the effective cancer chemotherapy. To address this issue, we developed the effective circumvention of multidrug resistance in cancer cells by a yolk-shell Fe3O4@MgSiO3 nanoplatform with the polymerpoly(ethylene glycol) and folic acid modifications can achieve active targeted delivery of anti-cancer drug by using combined magnetic and ligand targeting. The direct intracellular drug delivery of doxorubicin by nanocarrier was much more effectively than free DOX for multidrug resistant Hep-G2/MDR cancer cells. Besides the excellent biocompatibility, high drug loading efficiency, dual-targeting delivery, and controlled releasing behavior, in vivo experiments demonstrate that this nanocarrier can specifically deliver and concentrate doxorubicin hydrochloride in tumor sites to overcome drug resistance. It follows an alternative strategy for effective chemotherapy against drug resistant cancers by using rationally designed nanomaterial.
Medical subject headings
- Antineoplastic Agents
- Doxorubicin
- Drug Carriers
- Drug Resistance, Neoplasm
- Nanoparticles